Blunted type-5 metabotropic glutamate receptor-mediated polyphosphoinositide hydrolysis in two mouse models of monogenic autism

[1]  R. Kooy,et al.  Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network , 2022, Cells.

[2]  James Robert Brašić,et al.  Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study , 2022, Brain sciences.

[3]  A. Brownell,et al.  Longitudinal PET studies of mGluR5 in FXS using an FMR1 knockout mouse model , 2022, Translational neuroscience.

[4]  M. Bear,et al.  mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence , 2021, Frontiers in Psychiatry.

[5]  G. Fakhri,et al.  In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker , 2021, Scientific Reports.

[6]  James Robert Brašić,et al.  Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome , 2020, Brain sciences.

[7]  D. Alkon,et al.  Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice , 2020, Scientific Reports.

[8]  Qi Ding,et al.  Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model , 2020, Communications Biology.

[9]  S. Jacquemont,et al.  Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents , 2018, Scientific Reports.

[10]  Alcino J. Silva,et al.  The mouse as a model for neuropsychiatric drug development , 2018, Current Biology.

[11]  F. Nicoletti,et al.  In Vivo Non-radioactive Assessment of mGlu5 Receptor-Activated Polyphosphoinositide Hydrolysis in Response to Systemic Administration of a Positive Allosteric Modulator , 2018, Front. Pharmacol..

[12]  E. Klann,et al.  Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model , 2018, Neuropsychopharmacology.

[13]  Mark F. Bear,et al.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome , 2017, Nature Reviews Drug Discovery.

[14]  A. Frick,et al.  Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice , 2017, Nature Communications.

[15]  Michael Rabbia,et al.  Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results , 2017, Neuropsychopharmacology.

[16]  K. Gregory,et al.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery , 2017, Neuropharmacology.

[17]  M. Bear,et al.  β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X. , 2017, Cell reports.

[18]  M. Bear,et al.  Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome , 2016, The Journal of Neuroscience.

[19]  M. Bennett,et al.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice , 2016, Proceedings of the National Academy of Sciences.

[20]  L. Ceolin,et al.  Elevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model. , 2015, Cell reports.

[21]  Seth M. Kelly,et al.  Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. , 2015, Cell reports.

[22]  Andrew S. Felts,et al.  Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles , 2015, Neuropsychopharmacology.

[23]  F. Nicoletti,et al.  Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740 , 2014, Neuropharmacology.

[24]  S. Musumeci,et al.  Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism , 2014, Neuroscience & Biobehavioral Reviews.

[25]  P. Hickmott,et al.  Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model , 2014, The Journal of Neuroscience.

[26]  F. Nicoletti,et al.  Changes in mGlu5 Receptor-Dependent Synaptic Plasticity and Coupling to Homer Proteins in the Hippocampus of Ube3A Hemizygous Mice Modeling Angelman Syndrome , 2014, The Journal of Neuroscience.

[27]  E. Klann,et al.  Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome Mice , 2012, Neuron.

[28]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[29]  C. B. Smith,et al.  Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome , 2012, Neurobiology of Disease.

[30]  P. Worley,et al.  Disrupted mGluR5-Homer scaffolds mediate abnormal mGluR5 signaling, circuit function and behavior in a mouse model of Fragile X Syndrome , 2012, Nature Neuroscience.

[31]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[32]  P Jeffrey Conn,et al.  Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity , 2010, Molecular Pharmacology.

[33]  M. Bear,et al.  Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.

[34]  Mika Nakamoto,et al.  Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome , 2010, The Journal of Neuroscience.

[35]  E. Klann,et al.  Dysregulation of mTOR Signaling in Fragile X Syndrome , 2010, The Journal of Neuroscience.

[36]  J. Zhu,et al.  Ras Signaling Mechanisms Underlying Impaired GluR1-Dependent Plasticity Associated with Fragile X Syndrome , 2008, The Journal of Neuroscience.

[37]  I. Weiler,et al.  Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome , 2008, Proceedings of the National Academy of Sciences.

[38]  W. Lee,et al.  Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55α Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt* , 2008, Journal of Biological Chemistry.

[39]  K. M. Huber,et al.  Homer Interactions Are Necessary for Metabotropic Glutamate Receptor-Induced Long-Term Depression and Translational Activation , 2008, The Journal of Neuroscience.

[40]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[41]  Richard Paylor,et al.  Dynamic Translational and Proteasomal Regulation of Fragile X Mental Retardation Protein Controls mGluR-Dependent Long-Term Depression , 2006, Neuron.

[42]  B. Oostra,et al.  A Reduced Number of Metabotropic Glutamate Subtype 5 Receptors Are Associated with Constitutive Homer Proteins in a Mouse Model of Fragile X Syndrome , 2005, The Journal of Neuroscience.

[43]  J. Mandel,et al.  FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. , 2005, Human molecular genetics.

[44]  Q. Tang,et al.  The Scaffold Protein Homer1b/c Links Metabotropic Glutamate Receptor 5 to Extracellular Signal-Regulated Protein Kinase Cascades in Neurons , 2005, The Journal of Neuroscience.

[45]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[46]  E. Nagata,et al.  PI3 kinase enhancer–Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis , 2003, Nature Neuroscience.

[47]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Berridge,et al.  The versatility and universality of calcium signalling , 2000, Nature Reviews Molecular Cell Biology.

[49]  C. Barnes,et al.  Homer: a protein that selectively binds metabotropic glutamate receptors , 1997, Nature.

[50]  T. Knöpfel,et al.  Expression and Coupling to Polyphosphoinositide Hydrolysis of Group I Metabotropic Glutamate Receptors in Early Postnatal and Adult Rat Brain , 1997, The European journal of neuroscience.

[51]  R. Belmaker,et al.  Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex , 1988, Nature.

[52]  E. Costa,et al.  Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoceptors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.